Get Full Control Of Your T Cell Isolation For Your CAR T Cell Therapy Manufacturing

By Marine de Lageneste, Melissa Maggioni, Genna Luciani, Meerah Vijeyakumaran, and Debalina Basak

Cell therapies offer promising avenues for potentially treating malignancies that are currently deemed untreatable. Approaches like chimeric antigen receptor (CAR) T cell therapies are undergoing extensive evaluation in clinical trials, with several gaining approval, particularly for hematological tumors. Due to the increasing number of these therapies and the complex workflow needed to produce them, additional tools are necessary to ensure product consistency in a closed, automated process. The Sefia Select™ cell processing system fulfills this need, functioning as a closed instrument designed to automate various processing steps within the CAR T cell workflow. The introduction of MagnetSelect expands the capabilities of the Sefia Select system, facilitating magnetic T cell isolation and enhancing automation potential within the cell therapy process. In this study, we utilize the MagnetSelect application and CT-400 to demonstrate the automated magnetic isolation of CD4/CD8+ cells from fresh or frozen leukapheresis.